Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2012 2
2019 1
2020 1024
2021 1422
2022 1175
2023 705
2024 341
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

4,170 results

Results by year

Filters applied: . Clear all
Page 1
Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022).
Taylor SS, Coggins S, Barker EN, Gunn-Moore D, Jeevaratnam K, Norris JM, Hughes D, Stacey E, MacFarlane L, O'Brien C, Korman R, McLauchlan G, Salord Torres X, Taylor A, Bongers J, Espada Castro L, Foreman M, McMurrough J, Thomas B, Royaux E, Calvo Saiz I, Bertoldi G, Harlos C, Work M, Prior C, Sorrell S, Malik R, Tasker S. Taylor SS, et al. J Feline Med Surg. 2023 Sep;25(9):1098612X231194460. doi: 10.1177/1098612X231194460. J Feline Med Surg. 2023. PMID: 37732386 Free PMC article.
Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (10.4%). ...CONCLUSIONS AND RELEVANCE: Legally sourced remdesivir and GS-441524 products, either alone or used sequentially, were very …
Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (1 …
Remdesivir.
Bakheit AH, Darwish H, Darwish IA, Al-Ghusn AI. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2023;48:71-108. doi: 10.1016/bs.podrm.2022.11.003. Epub 2023 Feb 9. Profiles Drug Subst Excip Relat Methodol. 2023. PMID: 37061276 Free PMC article. Review.
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed …
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countri …
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis.
Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, Brophy JM, McDonald EG. Lee TC, et al. Clin Microbiol Infect. 2022 Sep;28(9):1203-1210. doi: 10.1016/j.cmi.2022.04.018. Epub 2022 May 19. Clin Microbiol Infect. 2022. PMID: 35598856 Free PMC article. Review.
Using neutral priors, the probabilities that remdesivir reduces mortality were 76.8%, 93.8%, and 14.7%, respectively. The probability that remdesivir reduced mortality by 1% was 77.4% for nonventilated patients requiring oxygen. CONCLUSIONS: Based on this meta-analy …
Using neutral priors, the probabilities that remdesivir reduces mortality were 76.8%, 93.8%, and 14.7%, respectively. The probability …
Remdesivir for the treatment of COVID-19.
Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Grundeis F, et al. Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2. Cochrane Database Syst Rev. 2023. PMID: 36695483 Free PMC article. Review.
BACKGROUND: Remdesivir is an antiviral medicine approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19). ...We excluded studies that evaluated remdesivir for the treatment of other coronavirus diseases. DATA COLLECTION AND ANALYSIS: We fol …
BACKGROUND: Remdesivir is an antiviral medicine approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19). . …
Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524.
Green J, Syme H, Tayler S. Green J, et al. J Vet Intern Med. 2023 Sep-Oct;37(5):1784-1793. doi: 10.1111/jvim.16804. Epub 2023 Jul 4. J Vet Intern Med. 2023. PMID: 37403259 Free PMC article.
BACKGROUND: GS-441524 has been successfully used to treat feline infectious peritonitis (FIP) in cats. However, the use of its prodrug, remdesivir, in combination with a PO GS-441524 containing product for the treatment of FIP has not yet been described. ...RESULTS: Cats r …
BACKGROUND: GS-441524 has been successfully used to treat feline infectious peritonitis (FIP) in cats. However, the use of its prodrug, r …
Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.
Coggins SJ, Norris JM, Malik R, Govendir M, Hall EJ, Kimble B, Thompson MF. Coggins SJ, et al. J Vet Intern Med. 2023 Sep-Oct;37(5):1772-1783. doi: 10.1111/jvim.16803. Epub 2023 Jul 13. J Vet Intern Med. 2023. PMID: 37439383 Free PMC article.
Investigation into the use of parent nucleotide analog remdesivir (GS-5734) is needed. OBJECTIVES: To assess efficacy and tolerability of remdesivir with or without transition to GS-441524 in cats with FIP and document clinical and clinicopathologic progression over …
Investigation into the use of parent nucleotide analog remdesivir (GS-5734) is needed. OBJECTIVES: To assess efficacy and tolerabilit …
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Spinner CD, et al. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. JAMA. 2020. PMID: 32821939 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n = 199), or standard care (n = 200). ...By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in …
INTERVENTIONS: Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of rem …
Remdesivir-Induced Bradycardia.
Kanagala SG, Dholiya H, Jhajj P, Patel MA, Gupta V, Gupta S, Wu SI, Jain R. Kanagala SG, et al. South Med J. 2023 Mar;116(3):317-320. doi: 10.14423/SMJ.0000000000001519. South Med J. 2023. PMID: 36863055 Free PMC article. Review.
Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because it curbs the viral load expansion. Among patients hospitalized as a result of lower respiratory tract infection, remdesivir proved t …
Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because …
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
Chatterjee B, Thakur SS. Chatterjee B, et al. Front Immunol. 2022 May 12;13:830990. doi: 10.3389/fimmu.2022.830990. eCollection 2022. Front Immunol. 2022. PMID: 35634324 Free PMC article. Review.
Better results were obtained with the remdesivir-baricitinib combination treatment for COVID-19 compared to the treatment with remdesivir alone. Notably, recovery from COVID-19 was found to be 8 days less via the remdesivir-baricitinib combination treatment a …
Better results were obtained with the remdesivir-baricitinib combination treatment for COVID-19 compared to the treatment with rem …
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.
Chen C, Fang J, Chen S, Rajaofera MJN, Li X, Wang B, Xia Q. Chen C, et al. BMC Infect Dis. 2023 Oct 9;23(1):672. doi: 10.1186/s12879-023-08525-0. BMC Infect Dis. 2023. PMID: 37814214 Free PMC article.
BACKGROUND: Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs. ...Compared with remdesivir alone …
BACKGROUND: Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to eval …
4,170 results